GlaxoSmithKline Pharmaceuticals Net Sales up 16%, PAT before

Mumbai, Maharashtra, India, Tuesday, February 19, 2013 -- (Business Wire India) 
GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the
fourth quarter ended 31st December, 2012. The growth in Net Sales was 16% and
Profit After Tax and before Exceptional Items was 7.4%. The core Pharmaceuticals
business grew by 15.9% for the quarter.  
For the year ended 31st December 2012, the growth in Net Sales was 11.2% and
Profit After Tax and before Exceptional Items was 7.3% while the core
Pharmaceuticals business grew by 12.5%.  
Despite a challenging operating environment, material cost increases and
significant investments in field force expansion, Profit before Exceptional
items and Tax grew by 7.3% and Profit before Investment Income, Depreciation and
Tax amounted to 32% of Net Sales. 
In 2012, the Company added new products across therapeutic areas. The company
launched Altargo™ in the dermatology portfolio; Volibris (Ambrisentan), a
non-sulphonamide class endothelin receptor antagonist (ERA) to treat pulmonary
arterial hypertension (PAH); HycamtinTM to fulfil unmet needs for patients with
advance cancers and relapsed small cell lung cancer (SCLC); Seretide®
Evohaler® - a Metered Dose Inhaler (MDI) with dose counter to help patients
keep a correct count of drug doses taken.  
The company forayed in CNS through the launch of Lamictal a newer epileptic drug
for treatment of partial and generalized seizures in children and adults. It is
also used in bipolar disorder for preventing mood episodes like depression and
mania.  
Branded generics were added to the range of products – Zimvir for herpes,
Uriscostat for gout, IVfer for iron deficiency and Ictacetam for epilepsy.  
Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said,
“In 2012, growth was broad based across the company. Mass markets grew well.
Vaccines continued the growth momentum by growing ahead of the market. Mass
Specialty and Specialty, both showed market competitive growth.” 
The Board recommended a dividend of Rs. 50 per Equity Share for the year
(previous year: Rs. 45 per Equity Share). If approved by the shareholders at the
Annual General Meeting, the Dividend will absorb Rs. 424 crores. The Dividend
Distribution Tax borne by the Company will amount to Rs. 64 crores. 
About GlaxoSmithKline: 
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc,
one of the world's leading research-based pharmaceutical and healthcare
companies, committed to improving the quality of human life by enabling people
to do more, feel better and live longer. For more information, visit
www.gsk-india.com.  
To view the Audited Consolidated Financial Results and Statement of Standalone
Audited Results, please click on the link given below: 
Audited Consolidated Financial Results for the year ended 31st December 2012 
Statement of Standalone Audited Results for the year ended 31st December, 2012 
Media contact details 
Nandini Goswami, General Manager Corporate Communications,
GlaxoSmithKline Consumer Healthcare Limited,
+91 (22) 24959203,
nandini.x.goswami@gsk.com 
Contributed via: Bloomberg Publisher WEB Service 
Provider ID: 90141f16baee4647bbbec3ee7f17e985 
-0- Feb/20/2013 04:24 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.